The cost‐effectiveness of NAT for HIV, HCV, and HBV in whole‐blood donations
- 21 May 2003
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 43 (6), 721-729
- https://doi.org/10.1046/j.1537-2995.2003.00392.x
Abstract
BACKGROUND: The risk of viral infection associated with blood transfusion is lower than ever before because of aggressive screening and testing practices. NAT technology has lowered that risk even further but at an additional cost to the health‐care system. STUDY DESIGN AND METHODS: Marginal cost‐effectiveness of NAT for HIV, HCV, and HBV in whole‐blood donations was calculated with a previously published Markov decision model. This model was updated with disease incidence data from all 2001 American Red Cross whole‐blood donations as well as window‐period data from the Retrovirus Epidemiology Donor Study (REDS). RESULTS: Whole‐blood donation NAT for HIV and HCV is expected to cost between $155 million (minipool NAT) and $428 million (single‐donation NAT) per year in the US and avert 4 to 7 HIV infections and 56 to 59 HCV infections. Adding HBV NAT would be expected to avert 9 to 37 HBV infections at an additional cost of between $39 million and $130 million per year. Overall, NAT would cost between $4.7 million and $11.2 million per quality‐adjusted life‐year saved. Discontinuing HIV p24 antigen and HBc testing would offset this somewhat. CONCLUSIONS: The cost‐effectiveness of whole‐blood NAT is poor. The testing cost would need to decrease significantly to bring the cost‐effectiveness in line with most other accepted medical practices.Keywords
This publication has 27 references indexed in Scilit:
- The Cost Effectiveness of Combination Antiretroviral Therapy for HIV DiseaseNew England Journal of Medicine, 2001
- NAT and blood safety: what is the paradigm?Transfusion, 2000
- Update of Cost-effectiveness Analysis for Solvent-Detergent-Treated PlasmaPublished by American Medical Association (AMA) ,1999
- Consequences of Nucleic Acid Amplification Testing for Blood Transfusion CentresVox Sanguinis, 1998
- The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infectionTransfusion Medicine Reviews, 1997
- Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and MedicineJAMA, 1996
- A cost-effectiveness analysis of the use of a mechanical barrier system to reduce the risk of mistransfusionTransfusion, 1996
- Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supplyPublished by American Medical Association (AMA) ,1994
- Long‐term survival after blood transfusionTransfusion, 1994
- Cost-effectiveness of preoperative autologons donation in coronary artery bypass graftingThe Annals of Thoracic Surgery, 1994